Orris
attachment

49 year old obese diabetic female patient with uncontrolled sugar levels and L foot pain over dorsal aspect 1 week ago. Sudden onset of pain. Swelling present and I and d was done. No much pus drained. But Slough was present slightly. Daily dressing going on and antibiotics taken for 5 days. Taking pain medications daily. Was on these medications daily. I have attached photo for reference . I changed to isyril m forte bd and daparyl vm 500 bd daily for now. Fbs is 180 ppbs 240. What should I do now to control

Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Searching PubMed

SGLT2 inhibitor diabetic foot infection amputation risk

Finding Sources
Finding Sources
Searching PubMed

SGLT2 inhibitor diabetic foot wound

Reading Article
Reading Article
Finding Sources
Now I have enough information to give a detailed, well-structured answer. Let me compile everything.

Clinical Assessment and Management Plan

What You're Dealing With

This is a diabetic foot infection (DFI) in a high-risk patient: obese, uncontrolled T2DM (FBS 180, PPBS 240), with a dorsal foot wound with slough post-I&D. The key concerns right now are:
  1. Inadequate glycemic control slowing wound healing and impairing immunity
  2. Drug selection issues - particularly the SGLT2i (Daparyl-VM contains dapagliflozin) in the context of an active foot wound
  3. Wound progression - slough presence suggests incomplete debridement/biofilm
  4. Risk stratification - need to rule out osteomyelitis and assess vascularity

URGENT: SGLT2 Inhibitor Concern

Daparyl-VM 500 contains dapagliflozin (SGLT2i) - this needs reassessment.
SGLT2 inhibitors carry FDA/EMA warnings for:
  • Fournier's gangrene (necrotizing fasciitis of the perineum)
  • Lower limb amputation risk (canagliflozin specifically, but class concern exists)
  • Increased genital and urinary tract infections
  • Euglycemic DKA risk, especially during infection/surgery
A 2026 retrospective study (Dumortier et al., Diabetes Care 2026, PMID 41739582) found SGLT2i use in DFU patients did NOT significantly increase amputation rates and was associated with lower 1-year mortality - however, this is a single-center retrospective study. A 2025 review (Li et al., Front Endocrinol 2025, PMID 40671916) concluded SGLT2is have not demonstrated significant protective effects on diabetic foot, unlike DPP-4 inhibitors and GLP-1RAs.
Practical recommendation: With an active infected foot wound, consider withholding dapagliflozin temporarily and switching to a safer alternative until the wound shows clear healing. Discuss with a diabetologist. The DPP-4i (vildagliptin in Isyryl M forte) is reasonable to continue.

Current Medications Analysis

DrugConcernAction
Isyryl M 2 Forte (Glimepiride 2mg + Metformin 1000mg SR) BDMetformin may be risky if infection worsens and causes dehydration/renal impairmentMonitor renal function; hold if creatinine rises
Daparyl VM 500 (Dapagliflozin 10mg + Vildagliptin 100mg + Metformin 500mg SR) BDDapagliflozin in active foot infection is a concern; also adds more metforminConsider switching to plain vildagliptin or adding insulin instead
Empayork-25 (Empagliflozin 25mg)Same SGLT2i class concern as aboveReview urgently
You are now combining two SGLT2 inhibitors (dapagliflozin + empagliflozin) - this is not standard practice and doubles the SGLT2-related risks.

Glycemic Control Strategy

Current targets: FBS 180, PPBS 240 - these are well above goal. Target should be FBS < 130, PPBS < 180 for wound healing.
Recommended approach for uncontrolled T2DM with active infection:
  1. Consider adding basal insulin (Glargine or NPH at bedtime, 0.1-0.2 units/kg/day as starting dose) - this is the most reliable way to bring FBS down quickly
  2. Simplify the regimen - you currently have 4 drugs with overlap; rationalise to:
    • Keep glimepiride + metformin (Isyryl M forte) BD
    • Keep vildagliptin (consider plain vildagliptin if Daparyl VM is withdrawn due to dapagliflozin)
    • Add basal insulin for FBS control
    • Hold/review both SGLT2 inhibitors
  3. Monitor blood glucose at least twice daily (fasting + 2h post-lunch) and titrate

Wound Management

Per Bailey & Love's Surgery and dermatology textbook guidance:
  1. Daily dressing is correct - continue
  2. Slough indicates incomplete debridement - consider:
    • Sharp/surgical debridement of remaining slough if viable tissue underneath
    • Enzymatic debriding agents (collagenase/papain-based dressings) if surgical debridement is not done
    • Negative pressure wound therapy (NPWT/VAC) if wound is deep enough
  3. Offloading the foot is mandatory - diabetic foot ulcers heal poorly without offloading; use a non-weight-bearing cast, total contact cast, or at minimum, appropriate footwear
  4. Wound swab for culture - if not done, do it now. A 5-day antibiotic course may be insufficient; need culture-directed therapy

Investigations to Do Now

  • Wound swab culture and sensitivity (aerobic + anaerobic if possible)
  • X-ray foot - to rule out osteomyelitis (look for periosteal reaction, cortical erosion)
  • MRI foot if osteomyelitis is suspected (more sensitive)
  • Doppler/ABI - to assess peripheral vascular disease (critical for healing potential)
  • CBC, CRP/ESR - inflammatory markers
  • HbA1c - to gauge longer-term control
  • RFT (renal function) - before continuing metformin/SGLT2i
  • Blood cultures if fever or systemic signs

Antibiotic Guidance

5 days may be too short for a diabetic foot infection with slough. Standard recommendations:
  • Mild/moderate DFI: 2-4 weeks total
  • If osteomyelitis: 6+ weeks
  • Empirical cover: gram-positive cocci (Staph, Strep) + gram-negatives + anaerobes if deep/ischemic
  • Common regimens: amoxicillin-clavulanate, or clindamycin + a quinolone, or piperacillin-tazobactam for severe cases
  • Adjust based on culture results

Red Flags - Refer/Admit If:

  • Wound deepening or extending despite treatment
  • Fever, chills, elevated WBC - signs of systemic sepsis
  • Evidence of osteomyelitis on imaging
  • Worsening vascular status (cold foot, pallor, absent pulses)
  • Ulcer probing to bone (highly predictive of osteomyelitis)
  • Crepitus (gas in tissue = surgical emergency)

Summary Action Plan

  1. Stop empagliflozin (Empayork-25) - two SGLT2is simultaneously is not appropriate
  2. Seriously reconsider dapagliflozin (in Daparyl VM) given active infected wound - at minimum, discuss with a diabetologist
  3. Add basal insulin to bring FBS toward < 130
  4. Extend antibiotics based on wound culture; ensure adequate duration (minimum 2 weeks)
  5. Debride slough - surgical or enzymatic
  6. Offload the foot - strict non-weight bearing
  7. Order X-ray foot + wound swab + RFT + CBC + HbA1c
  8. Refer to a multidisciplinary diabetic foot team if available (vascular surgeon, orthopedic/podiatrist, diabetologist, wound care nurse)
Important note: This clinical advice is provided for professional guidance. Final decisions must be individualized based on full clinical assessment and local protocols. Active diabetic foot infections are complex and can escalate rapidly.

?

Could you clarify what you'd like to know? For example:
  • Did something in my previous answer need more explanation?
  • Do you have a new question about this patient?
  • Are you asking about a specific medication, the wound, or the blood sugar management?
This is a shared conversation. Sign in to Orris to start your own chat.